Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MVA-NP+M1 (AGE1.CR.pIX) in Healthy Adults
NCT03277456Phase 1Completed
- Sponsor
- Barinthus Biotherapeutics
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VTP-100 in influenza, sponsored by Barinthus Biotherapeutics. Primary endpoints: Measure of local reactogenicity following intramuscular injection of MVA-NP+M1 at 7 days, Measure of systemic reactogenicity following intramuscular injection of MVA-NP+M1 at 7 days and 3 more. Started Sep 2017; status: completed.
02
Drugs
VTP-100
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03277456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277456.